Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Age Related Macular Degeneration
Interventions
DRUG

Ranibizumab

Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.

Trial Locations (2)

L8G 5E4

St. Joseph's Healthcare Hamilton Regional Eye Centre, Hamilton

M5T 2S8

Toronto Western Hospital Eye Clinic, Toronto

All Listed Sponsors
collaborator

Canadian National Institute for the Blind

OTHER

lead

McMaster University

OTHER

NCT01363570 - Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes | Biotech Hunter | Biotech Hunter